A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标： 本方案的主要目的是比较无类固醇免疫抑制剂与他克莫司（TMF）、吗替麦考酚酯（CellCept）和达克珠单抗（Zenapax）联合诱导与基于类固醇的免疫抑制剂的安全性和疗效。 他克莫司/MPA PK子研究的具体目的是确定他克莫司和吗替麦考酚酯在入组方案SNS 01的儿童肾移植患者中的生物利用度。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: The primary objective of this protocol is to compare the safety and efficacy of steroid-free immunosuppression, given in combination with tacrolimus (Prograf), mycophenolate mofetil (CellCept) and daclizumab (Zenapax) induction with steroid-based immunosuppression. The specific aim of the tacrolimus/MPA PK sub-study is to determine the bioavailability of tacrolimus and mycophenolate mofetil in pediatric renal transplant patients enrolled in Protocol SNS01.